Skip to search formSkip to main contentSkip to account menu

CERESTAT

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

aptiganel

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2001
Highly Cited
2001
A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke
2000
2000
Efficacy of a new neuroprotective agent, gacyclidine, in a model of rat spinal cord injury.
Prevention of the immediate excitotoxic phase occurring in response to spinal cord injury (SCI) is a major issue to reduce the… 
1999
1999
[Neuroprotection in ischemia of the retina in an animal model].
QUESTION The NMDA-receptorantagonist memantin is neuroprotective in retinal ischemia. Does this also apply to the NMDA… 
1998
1998
Neuroprotective properties of aptiganel HCL (Cerestat) following controlled cortical impact injury.
Recent studies revealed a neuroprotective effect of the non-competitive NMDA receptor antagonist Aptiganel HCL (Cerestat CNS 1102… 
1998
1998
NMDA antagonists for stroke and head trauma: current status.
The clinical failures with selfotel, cerestat and eliprodil have evoked a significant degree of caution regarding the clinical… 
Highly Cited
1997
Highly Cited
1997
Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers.
In the mammalian central nervous system, the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors may play an important… 
1997
1997
Immediate-early gene expression in ovine brain after hypothermic circulatory arrest: effects of aptiganel.
1997
1997
Clinical Experience with the NMDA Ion Channel Blocker, Aptiganel Hydrochloride (CERESTAT®)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)